JP2008546373A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008546373A5 JP2008546373A5 JP2008504018A JP2008504018A JP2008546373A5 JP 2008546373 A5 JP2008546373 A5 JP 2008546373A5 JP 2008504018 A JP2008504018 A JP 2008504018A JP 2008504018 A JP2008504018 A JP 2008504018A JP 2008546373 A5 JP2008546373 A5 JP 2008546373A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- glp
- polypeptide
- mimetibody
- integer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 60
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 52
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 52
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims 52
- 229920001184 polypeptide Polymers 0.000 claims 48
- 102000004196 processed proteins & peptides Human genes 0.000 claims 48
- 108060003951 Immunoglobulin Proteins 0.000 claims 21
- 229940079593 drug Drugs 0.000 claims 21
- 239000003814 drug Substances 0.000 claims 21
- 102000018358 immunoglobulin Human genes 0.000 claims 21
- 239000000203 mixture Substances 0.000 claims 17
- 108020004707 nucleic acids Proteins 0.000 claims 16
- 102000039446 nucleic acids Human genes 0.000 claims 16
- 150000007523 nucleic acids Chemical class 0.000 claims 16
- 230000002950 deficient Effects 0.000 claims 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 10
- 230000000975 bioactive effect Effects 0.000 claims 9
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 8
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 8
- 238000009472 formulation Methods 0.000 claims 8
- 239000004480 active ingredient Substances 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 102000004877 Insulin Human genes 0.000 claims 5
- 108090001061 Insulin Proteins 0.000 claims 5
- 229940125396 insulin Drugs 0.000 claims 5
- 150000001413 amino acids Chemical group 0.000 claims 4
- 210000003403 autonomic nervous system Anatomy 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims 4
- 238000007912 intraperitoneal administration Methods 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 238000001361 intraarterial administration Methods 0.000 claims 3
- 238000007918 intramuscular administration Methods 0.000 claims 3
- 238000007919 intrasynovial administration Methods 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 3
- 238000007914 intraventricular administration Methods 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 238000007920 subcutaneous administration Methods 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 101000883510 Bos taurus Chitinase-3-like protein 1 Proteins 0.000 claims 2
- 101001021281 Homo sapiens Protein HEXIM1 Proteins 0.000 claims 2
- 101000993459 Mus musculus Metal transporter CNNM1 Proteins 0.000 claims 2
- 102100036307 Protein HEXIM1 Human genes 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940041181 antineoplastic drug Drugs 0.000 claims 2
- 239000010836 blood and blood product Substances 0.000 claims 2
- 229940125691 blood product Drugs 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 239000003792 electrolyte Substances 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 238000007913 intrathecal administration Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000004060 metabolic process Effects 0.000 claims 2
- 235000016709 nutrition Nutrition 0.000 claims 2
- 210000000664 rectum Anatomy 0.000 claims 2
- 210000002345 respiratory system Anatomy 0.000 claims 2
- 230000009261 transgenic effect Effects 0.000 claims 2
- 210000001215 vagina Anatomy 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000003302 anti-idiotype Effects 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000000084 colloidal system Substances 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000000409 cytokine receptor agonist Substances 0.000 claims 1
- 239000000430 cytokine receptor antagonist Substances 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 230000003914 insulin secretion Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 239000005022 packaging material Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000003860 topical agent Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000037317 transdermal delivery Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2005097175 | 2005-03-28 | ||
| PCT/US2005/046884 WO2007081302A2 (en) | 2005-03-28 | 2005-12-22 | Human glp-1 mimetibodies, compositions, methods and uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008546373A JP2008546373A (ja) | 2008-12-25 |
| JP2008546373A5 true JP2008546373A5 (enExample) | 2009-03-05 |
Family
ID=38256744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008504018A Pending JP2008546373A (ja) | 2005-03-28 | 2005-12-22 | ヒトｇｌｐ−１ミメティボディ、組成物、方法および用途 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1871811A4 (enExample) |
| JP (1) | JP2008546373A (enExample) |
| KR (1) | KR20080005378A (enExample) |
| CN (1) | CN101389346A (enExample) |
| AU (1) | AU2005339797A1 (enExample) |
| BR (1) | BRPI0520168A2 (enExample) |
| CA (1) | CA2603359A1 (enExample) |
| CR (1) | CR9481A (enExample) |
| IL (1) | IL186307A0 (enExample) |
| MX (1) | MX2007011975A (enExample) |
| NO (1) | NO20075272L (enExample) |
| WO (1) | WO2007081302A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200843794A (en) * | 2006-12-21 | 2008-11-16 | Centocor Inc | Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles |
| CN111574583B (zh) * | 2020-04-10 | 2021-06-25 | 上海海路生物技术有限公司 | 蛋白复性试剂及其应用 |
| CN120741086A (zh) * | 2024-07-26 | 2025-10-03 | 荣耀终端股份有限公司 | 模拟人体组织液及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000046380A2 (en) * | 1999-02-08 | 2000-08-10 | Chiron Corporation | Fibroblast growth factor receptor-immunoglobulin fusion |
| NZ525577A (en) * | 2000-12-07 | 2005-05-27 | Lilly Co Eli | Glucagon-Like Peptide 1 heterologous fusion proteins for the treatment of non-insulin dependent diabetes mellitus |
| JP2006504406A (ja) * | 2002-06-28 | 2006-02-09 | セントカー・インコーポレーテツド | 哺乳動物のｃｈ１欠失ミメティボディ、組成物、方法および使用 |
| AU2003256336A1 (en) * | 2002-06-28 | 2004-01-19 | Centocor, Inc. | Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| EP1644416A4 (en) * | 2003-06-30 | 2007-08-29 | Centocor Inc | ANTI-TARGET AND GENETICALLY MODIFIED IMMUNOGLOBULIN-DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES |
| AU2005231359A1 (en) * | 2004-03-31 | 2005-10-20 | Centocor, Inc. | Human GLP-1 mimetibodies, compositions, methods and uses |
-
2005
- 2005-12-22 EP EP05858723A patent/EP1871811A4/en not_active Withdrawn
- 2005-12-22 MX MX2007011975A patent/MX2007011975A/es not_active Application Discontinuation
- 2005-12-22 CN CNA200580049931XA patent/CN101389346A/zh active Pending
- 2005-12-22 JP JP2008504018A patent/JP2008546373A/ja active Pending
- 2005-12-22 AU AU2005339797A patent/AU2005339797A1/en not_active Abandoned
- 2005-12-22 KR KR1020077024874A patent/KR20080005378A/ko not_active Withdrawn
- 2005-12-22 BR BRPI0520168-3A patent/BRPI0520168A2/pt not_active Application Discontinuation
- 2005-12-22 CA CA002603359A patent/CA2603359A1/en not_active Abandoned
- 2005-12-22 WO PCT/US2005/046884 patent/WO2007081302A2/en not_active Ceased
-
2007
- 2007-09-25 IL IL186307A patent/IL186307A0/en unknown
- 2007-10-15 NO NO20075272A patent/NO20075272L/no not_active Application Discontinuation
- 2007-10-29 CR CR9481A patent/CR9481A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008525477A5 (enExample) | ||
| JP2007508011A5 (enExample) | ||
| JP2005512522A5 (enExample) | ||
| CN107207618B (zh) | 包含glp和免疫球蛋白杂合fc的融合多肽及其用途 | |
| KR100989647B1 (ko) | 식습관의 변화 | |
| US9944687B2 (en) | Compounds and their effects on feeding behaviour | |
| EP1729792B1 (en) | Y4 selective receptor agonist for therapeutic interventions | |
| ME02185B (me) | Anti-il-6 antitela, preparati, postupci pripreme i upotrebe | |
| KR20070004078A (ko) | 인간 ｇｌｐ-1 모방체, 조성물, 방법 및 용도 | |
| TR201802689T4 (tr) | Glukagon benzeri peptit-2 (glp-2) analogları. | |
| US20180280480A1 (en) | Compositions and peptides having dual glp-1r and glp-2r agonist activity | |
| JP2010514699A (ja) | インスリン感受性および脂質プロファイルを改善するための長時間作用型ｇｌｐ−１受容体アゴニストの使用 | |
| TW201934571A (zh) | Ｆｇｆ２１變體、融合蛋白及其應用 | |
| JP2020533302A (ja) | 肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１ | |
| CN105801705A (zh) | 含胰高血糖素样肽-1和免疫球蛋白杂合Fc的融合多肽及其用途 | |
| TW202028228A (zh) | 人類澱粉素(amylin)類似物多肽及使用方法 | |
| CN114848799A (zh) | 用于肌肉减少症治疗的包括胰高血糖素样肽-1受体激动剂的药物组合物 | |
| ES2660739T3 (es) | Tratamiento de cáncer de pulmón usando el inhibidor SIS3 de Smad3 | |
| TW202237628A (zh) | 長效性類升糖素多肽-1(glp-1)受體促效劑及其使用方法 | |
| CN115485292A (zh) | 新的双特异性蛋白及其用途 | |
| JP2008546373A5 (enExample) | ||
| JP2021505656A (ja) | グルカゴン様ペプチド | |
| JP2009526750A5 (enExample) | ||
| KR20090077935A (ko) | 내당능 장애 관련 증상을 예방하거나 치료하기 위한 인간 ｅｐｏ 수용체 작용제, 조성물, 방법 및 용도 | |
| CN104918954A (zh) | N-末端电荷发生变化的胰岛素分泌肽衍生物 |